Link Cell Therapies upsizes Series A financing to $90M to advance logic-gated CAR-T therapies for solid tumors and hematologic malignancies.
Amount Raised
$30 Million
Round Type
Series A
South San FranciscoBiotechnologyHealth CareTherapeuticsDescription
Link Cell Therapies announced a $30 million expansion of its Series A financing, upsizing the round from $60 million to $90 million. The company initiated clinical dosing for LNK001, its lead AND-gated CAR-T therapy targeting CAIX and ENPP3 in a Phase 1 study at MD Anderson Cancer Center for advanced clear cell renal cell carcinoma. The additional capital will advance a second solid tumor program in colorectal cancer and expand the overall pipeline. The company also announced three executive leadership additions, including a new CEO.
Quick answer
Link Cell Therapies raised $30 Million in a Series A round, dated September 28, 2026. Link Cell Therapies is based in South San Francisco, California, United States.
- How much did Link Cell Therapies raise?
- Link Cell Therapies raised $30 Million in a Series A round on September 28, 2026.
- What does Link Cell Therapies do?
- Link Cell Therapies is a biotechnology company focused on advancing CAR-T therapies for solid and liquid tumors.
- Where is Link Cell Therapies based and how big is it?
- Link Cell Therapies is based in South San Francisco, California, United States. Fundz records about 23 employees.
- Who are the decision-makers at Link Cell Therapies?
- Fundz holds 2 contacts at Link Cell Therapies, including the Chief Operating Officer. Names and contact details are shown to Fundz members.
Source: Fundz verified event record.
Who else raised in Therapeutics and Biotechnology around the same time
Companies in the same sectors as Link Cell Therapies that raised within 45 days of this round, from Fundz verified event records.
- Orakl Oncology raised $34M (Series A) on November 12, 2026.
- Neurosterix raised $105M (Series B) on November 11, 2026.
- VectorY raised $83M on November 11, 2026.
- Oyster Therapeutics raised $60M (Series A) on November 10, 2026.
- SRTD biotech raised $35M (Seed) on November 9, 2026.
- BioVie raised $4.7M (Post-IPO Equity) on November 6, 2026.
Who to call at Link Cell Therapies, and when
A new round usually means Link Cell Therapies is about to hire and buy. The teams that reach out first get the meeting.
- An alert the day Link Cell Therapies raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Link Cell Therapies, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Link Cell Therapies. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Link Cell Therapies raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
Funding Insights
What this usually meansLink Cell Therapies raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.